BioMarin Pharmaceuticals (BMRN) 37.24 -0.84

BioMarin Pharmaceuticals, Inc.
(BMRN) 37.24 -0.84

Last Trade:	37.21	Day Range:	37.125 - 37.92
Trade Time:	08:02PM	52wk Range:	23.0902 - 38.66
Prev. Close:	38.05	Market Cap:	4.25B
Open:	37.92	Div Yield:	0
Volume:	1325963	PE:
EPS:	-0.26

The Latest On BMRN

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12 3:49pm

JPMorgan Confab Kicks Off Biotech 2012 1/5/12 11:46am

Stifel Nicolaus Maintains Hold on BioMarin Pharmaceuticals 12/9/11 9:29am

Brean Murray Maintains Hold on BioMarin Pharma After Analyst Day 12/9/11 9:28am

BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority for $81M 11/30/11 4:00pm

Wedbush Maintains Neutral, $34 Target on BioMarin Pharmaceuticals 11/30/11 8:21am

BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA 11/29/11 4:00pm

BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility 11/28/11 9:01am

UPDATE: J.P. Morgan Raises PT on BioMarin Pharmaceuticals to $38 10/28/11 8:08am

JP Morgan Raises PT on BioMarin Pharmaceuticals from $35 to $38, Maintains Overweight 10/28/11 6:24am

UPDATE: Jefferies Raises PT on BioMarin Pharma to $38 10/17/11 9:00am

Jefferies Raises PT on BioMarin Pharmaceuticals to $38 10/17/11 6:31am

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12

JPMorgan Confab Kicks Off Biotech 2012 1/5/12

Stifel Nicolaus Maintains Hold on BioMarin Pharmaceuticals 12/9/11

Brean Murray Maintains Hold on BioMarin Pharma After Analyst Day 12/9/11

BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority for $81M 11/30/11

Wedbush Maintains Neutral, $34 Target on BioMarin Pharmaceuticals 11/30/11

BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA 11/29/11

BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility 11/28/11

UPDATE: J.P. Morgan Raises PT on BioMarin Pharmaceuticals to $38 10/28/11

JP Morgan Raises PT on BioMarin Pharmaceuticals from $35 to $38, Maintains Overweight 10/28/11

UPDATE: Jefferies Raises PT on BioMarin Pharma to $38 10/17/11

Jefferies Raises PT on BioMarin Pharmaceuticals to $38 10/17/11

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12

Stocks to Watch for Monday 8/01/2011: Fresh 52 Week Highs and Lows 7/31/11

Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows 7/20/11

Stocks to Watch for Thursday 7/14/2011: Fresh 52 Week Highs and Lows 7/14/11

BMRN Acquires ZyStor Therapeutics 8/18/10

Benzinga’s Top Pre-Market NASDAQ Losers (SYKE, BMRN, IVAC, ARMH) 8/3/10

Benzinga’s Volume Movers (TRIT, LULU, GIII, BMRN, CKEC) 3/25/10

Stocks That Created New 52-Week Highs (BGCP, BIIB, BMRN, BJRI, BRCM) 3/10/10

Mid Cap Biotechs May Outperform In 2010 1/15/10

5 Stocks with a Change in Guidance (BMRN, HTZ, LTD) 10/29/09

Jim Cramer Would Sell COMS, BMRN, EGLE, HURN, WWE 9/17/09

Stifel Nicolaus Maintains Hold on BioMarin Pharmaceuticals 12/9/11

Brean Murray Maintains Hold on BioMarin Pharma After Analyst Day 12/9/11

Wedbush Maintains Neutral, $34 Target on BioMarin Pharmaceuticals 11/30/11

UPDATE: J.P. Morgan Raises PT on BioMarin Pharmaceuticals to $38 10/28/11

JP Morgan Raises PT on BioMarin Pharmaceuticals from $35 to $38, Maintains Overweight 10/28/11

UPDATE: Jefferies Raises PT on BioMarin Pharma to $38 10/17/11

Jefferies Raises PT on BioMarin Pharmaceuticals to $38 10/17/11

Piper Jaffray Overweight on BioMarin Pharmaceutical (BMRN 10/3/11

UPDATE: Deutsche Bank Upgrades BioMarin Pharmaceuticals to Buy 9/28/11

Deutsche Bank Upgrades BioMarin Pharmaceuticals to Buy, PT Raised to $40 9/28/11

UPDATE: Piper Jaffray Raises Price Target On BioMarin Pharmaceuticals to $43 9/21/11

UPDATE: Piper Jaffray Upgrades BioMarin To Overweight 8/10/11

Trade BMRN
NOW!

Partner Headlines

Zacks #5 Rank Additions for Wednesday - Tale of the Tape 2/8/12

Qiagen Expands with New Deals - Analyst Blog 1/12/12

8 Stocks Hitting New Highs Today 1/6/12

BioMarin's Facility Expansion Backed - Analyst Blog 12/22/11

Pipeline Progress at BioMarin - Analyst Blog 12/1/11

BioMarin Upped to Neutral - Analyst Blog 11/16/11

BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper sells 2,500 Shares 11/3/11

BioMarin Pharmaceutical Inc. Reports Operating Results (10-Q) 10/31/11

Loss at BioMarin Wider-Than-Expected - Analyst Blog 10/31/11

BioMarin Downgraded - Analyst Blog 10/17/11

BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper sells 18,379 Shares 10/11/11

Press Releases

Critical Alerts For AIG, Micron Technology, Medcohealth Solutions, Hasbro, and BioMarin Released By Seven Summits Research 2/7/12 Newswire Story

BioMarin to Present at the BIO CEO & Investor Conference 2/7/12 GlobeNewswire Story

MethylGene Announces the Appointment of Dr. Henry J. Fuchs to its Board of Directors 2/2/12 Marketwire Story

BioMarin to Host Fourth Quarter and Full Year 2011 Financial Results Conference Call and Webcast on Thursday, February 16 at 5:00 p.m. ET 1/23/12 GlobeNewswire Story

BioMarin to Present at the J.P. Morgan Healthcare Conference 1/3/12 Newswire Story

BioMarin Announces IND for BMN-111 for Achondroplasia is Active 1/3/12 Newswire Story

BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility 12/19/11 Newswire Story

Quarterly Changes to the NASDAQ Q-50 Index 12/9/11 GlobeNewswire Story

Highlights from BioMarin's Research & Development Day 12/8/11 Newswire Story

BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority 11/30/11 Newswire Story

BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA 11/29/11 Newswire Story

BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility 11/28/11 Newswire Story

Get the latest BMRN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for BioMarin Pharmaceuticals, Inc. stock price.

BioMarin Pharmaceuticals, Inc. by YCharts